Sjogren's Syndrome an Update on Disease Pathogenesis, Clinical
Clinical Immunology 203 (2019) 81–121 Contents lists available at ScienceDirect Clinical Immunology journal homepage: www.elsevier.com/locate/yclim Review Article Sjogren’s syndrome: An update on disease pathogenesis, clinical T manifestations and treatment ⁎ Frederick B. Vivinoa, , Vatinee Y. Bunyab, Giacomina Massaro-Giordanob, Chadwick R. Johra, Stephanie L. Giattinoa, Annemarie Schorpiona, Brian Shaferb, Ammon Peckc, Kathy Sivilsd, ⁎ Astrid Rasmussend, John A. Chiorinie, Jing Hef, Julian L. Ambrus Jrg, a Penn Sjögren's Center, Penn Presbyterian Medical Center, University of Pennsylvania Perelman School of Medicine, 3737 Market Street, Philadelphia, PA 19104, USA b Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, 51 N. 39th Street, Philadelphia, PA 19104, USA c Department of Infectious Diseases and Immunology, University of Florida College of Veterinary Medicine, PO Box 100125, Gainesville, FL 32610, USA d Oklahoma Medical Research Foundation, Arthritis and Clinical Immunology Program, 825 NE 13th Street, OK 73104, USA e NIH, Adeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research, Building 10, Room 1n113, 10 Center DR Msc 1190, Bethesda, MD 20892-1190, USA f Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing 100044, China g Division of Allergy, Immunology and Rheumatology, SUNY at Buffalo School of Medicine, 100 High Street, Buffalo, NY 14203, USA 1. Introduction/History and lacrimal glands [4,11]. The syndrome is named, however, after an Ophthalmologist from Jonkoping, Sweden, Dr Henrik Sjogren, who in Sjogren’s syndrome (SS) is one of the most common autoimmune 1930 noted a patient with low secretions from the salivary and lacrimal diseases. It may exist as either a primary syndrome or as a secondary glands.
[Show full text]